University of Guelph’s Dr. Charlotte Winder named 2023 Metacam® 20 Bovine Welfare Award winner
University of Guelph’s Dr. Charlotte Winder named 2023 Metacam® 20 Bovine Welfare Award winner
Search
Alberta’s Dr. Karen Schwartzkopf-Genswein named 2022 Metacam® 20 Bovine Welfare Award winner
Award recognizes outstanding contributions to the welfare of animals in Canada
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Introducing Ingelvac Provenza™ — Stop influenza A Virus in swine where it starts
Protect your dog from parasites, inside and out
Protect your dog from parasites, inside and out
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Virtual care pharmacy services offered in Alberta long-term care facilities
Virtual care pharmacy services offered in Alberta long-term care facilities
Collaboration key to meeting consumers’ expectations for better animal welfare
Collaboration key to meeting consumers’ expectations for better animal welfare
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner
University of Saskatchewan’s Dr. Diego Moya named 2024 Metacam® Bovine Welfare Award winner
Award recognizes outstanding contributions to advancing animal welfare in Canada
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Osteoarthritis in dogs: Protecting your pet from pain
Osteoarthritis in dogs: Protecting your pet from pain
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
UBC launches Canada's first graduate blockchain training path
UBC launches Canada's first graduate blockchain training path
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis
New clinical trial data published in the New England Journal of Medicine, showed that spesolimab, a novel IL-36R antibody treatment, was effective in rapidly treating adult patients with generalized pustular psoriasis (GPP) experiencing a flare.